Gilead Pullback!Three bear bars is a concern but, with 2 different measured moves objects above and a solid trend upwards, I think its worth a shot for a long. If it is worth anything, the whole industry seems to be trending positively.
GILD trade ideas
Gilead Sciences (GILD): Will Support Hold or Will We See a Drop?We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from there.
However, the outlook remains uncertain. We hope that the stock does not fall below this range bottom, as it would prompt us to consider cutting it. Our first take-profit target is at the range high around $86.5, but reaching this level will take time as Gilead Sciences is currently underperforming.
Unlike most other stocks, Gilead Sciences operates in the research sector, not the tech sector. This means it follows a different cycle and is influenced by different capital flows. It tends to perform well when tech stocks do poorly. If tech stocks remain bullish, Gilead Science might continue to struggle. However, if there's a shift, Gilead Science could reverse and potentially reach up to $123, though this is quite far off.
We are holding our position for now, hoping not to cut if the stock falls out of the range. If it does, we will take necessary action.
Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17%, and we don’t want to dictate when to take profits. If you’re in, do your own research and take profits whenever you feel comfortable—it's all up to you 👍.
If you take a closer look, you’ll see that NASDAQ:GILD has been following a nice upward pattern: a surge, then three candles down, then another surge. I’m not sure how long this pattern will hold, but as long as we don’t retrace too much, we should be fine. I also like that we’re respecting all the key levels. The RSI is about to be overbought, so we might see another three candles down, but this time it could be a deeper pullback.
We’ll see how it plays out, but we’re very pleased with this swing trade so far. Congratulations to everyone who’s been riding this wave 🍾.
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range again but rather settle in the middle. If NASDAQ:GILD reclaims this range high, it could provide even more upside and new opportunities.
We are also raising our stop loss to $65.80 to lock in gains. Gilead serves as our "natural hedge" against broader risk-on market conditions, and with a 40% bounce from the range low at the same time the S&P 500 is hitting new all-time highs, it’s clear that Gilead can benefit as well.
We’re keeping a close eye on this stock, and if another opportunity arises, we’ll be ready to act.
Swing Trade Potential Following Completed BottomNASDAQ:GILD has completed its bottom AND sustained the run up from the bottom completion, which provides strong support. The stock is now heading toward the previous resistance highs from January; this is not strong resistance. The type of sideways trend developing now builds energy that can easily move above that weaker resistance. Swing trade watch. Earnings are in a month.
GILD potential Buy setupReasons for bullish bias:
- Price gave LH breakout
- Strong bullish divergence
- Price bounce from support zone
Here are the recommended trading levels:
Entry Level(CMP): 68.30
Stop Loss Level: 60.81
Take Profit Level 1: 76.05
Take Profit Level 2: 83.67
Take Profit Level 3: Open
GILD is BullishPrice was in a strong downtrend, however the bulls woke up and won control of the price action, following bullish RSI divergence on daily time frame, now first higher high and higher low are defined, and if previous higher high is broken, we can expect a bullish rally according to Dow theory. Targets are mentioned on the chart.
Bullish reversal is a clear confirmationNASDAQ:GILD had a strong bullish buying pressure at the bottom with the support of a volume spike. Furthermore, it has broken out of the downtrend line. Double bottom formation is confirmed and Mid-term stochastic is showing confirmation of oversold together with divergence.
Hence, we will buy on market spot upon open or a retracement to 69.11 or 64.85.
GILD will be selected for the new Tamiflu vaccine for Pandemic2It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!).
After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines.
The call options on this company are going crazy right now, July, August have a ton of OTM calls being bought, almost like someone is expecting this company to get the greenlight on something major. You could effectively buy .05 OTM calls on this company, but I'd wait a little longer. The TTM squeeze shows the last leg down is being finished. If the market's capitulate a little more, this would be a perfect time to buy those calls for this company.
GILD potential Buy setupReasons for bullish bias:
- Safe entry at LH breakout
- Price bounce from support
- Bullish divergence
- Positive Earnings
Here are the recommended trading levels:
Entry Level(Buy stop): 68.59
Stop Loss Level: 64.05
Take Profit Level 1: 71.98
Take Profit Level 2: 84.79
Take Profit Level 3: Open
GILD falling wedgeHi traders,
Focusing on Gilead Sciences, Inc. (ticker symbol: GILD), we can see that it has formed a
falling wedge pattern over the past few weeks, indicating a potential bullish reversal.
Despite recent challenges, there are compelling reasons to consider a long position in this
stock.
Gilead Sciences has been a key player in the pharmaceutical industry, known for its
innovative treatments in areas such as HIV/AIDS, hepatitis, and more recently, COVID-19.
Despite recent market pressures, GILD fundamental strength remains intact, supported
by its diverse portfolio of blockbuster drugs and ongoing research and development efforts.
The falling wedge pattern, coupled with the oversold Relative Strength Index (RSI) suggests
that the stock is undervalued and may be ripe for a reversal. As the stock approaches the
apex of the falling wedge, and the key support level, we expect the trend reversal. The breakout above the upper trendline could signal a bullish move.
Furthermore, recent news indicates that Gilead Sciences is exploring strategic initiatives to
enhance its pipeline and drive future growth. This includes potential partnerships,
acquisitions, and advancements in its drug development programs, which could serve as
catalysts for a turnaround in the stock's performance.
As the breakout of the falling wedge pattern becomes imminent, considering a long position
upon confirmation of a break above the upper trendline may present an attractive
opportunity for traders seeking to capitalize on the potential bullish reversal.
Buy once the breakout occurs.
3 take profit levels / targets are shown on the chart
Gilead Sciences (GILD): Chances in Pharma Beyond TechGilead Sciences (GILD): NASDAQ:GILD
We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at $123.27, marking our all-time high.
This figure is our target for the minimum achievement for Wave 3. It's crucial, and significantly, we anticipate a high selling pressure at this level. Zooming in, we presume we are in Wave 2, expected to conclude between 61.8% and 78.6% retracement. This positions us with a relatively favorable risk-to-reward ratio on the daily chart. Should we drop below this 78.6% retracement level, we could fall back to $56. If that happens, we'll face a problem, potentially falling further for Wave (4) to a maximum of $30. If this decline doesn't materialize, we'll continue to anticipate an upward movement.
GILD potential buy setupReasons for bullish bias:
- Bounce from strong support
- Bullish engulfing candle formed at weekly closing
Entry Level(CMP): 75.58
Stop Loss Level: 71.20
Take Profit Level 1: 79.96
Take Profit Level 2: 84.34
Take Profit Level 3: Open
GILD Gilead Sciences Options Ahead of EarningsIf you haven`t bought GILD before the previous earnings:
Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week,
I would consider purchasing the 80usd strike price Calls with
an expiration date of 2024-6-21,
for a premium of approximately $3.10.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Gilead's Trodelvy Faces Setback in Lung Cancer Trial
In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival for previously treated patients. Despite a noted three-month survival benefit for a subgroup, the overall outcome fell short of statistical significance. This setback raises questions about Trodelvy's potential in lung cancer and underscores the challenges in developing effective treatments for this complex disease.
The Trial and Its Implications:
The trial involved 603 patients with metastatic or advanced NSCLC who had experienced disease progression despite standard platinum-based chemotherapy and checkpoint inhibitor treatment. Gilead reported that patients receiving Trodelvy exhibited longer survival compared to those on chemotherapy, but the difference did not reach statistical significance. Notably, a subgroup of patients who did not respond to their last checkpoint inhibitor treatment showed a more than three-month survival benefit. Gilead plans to discuss these results with regulators and present the full data at an upcoming medical meeting, indicating a commitment to transparent communication and a thorough examination of the findings.
Exploring Trodelvy's Potential:
Despite the setback, Gilead ( NASDAQ:GILD ) remains optimistic about Trodelvy's potential in metastatic NSCLC. The company emphasizes the drug's positive impact on a specific patient subgroup and expresses confidence in Trodelvy's broader lung cancer clinical development program. Gilead's Chief Medical Officer, Merdad Parsey, highlights ongoing Phase 2 and 3 trials investigating Trodelvy in combination with Keytruda as an initial treatment for NSCLC patients. The company's dedication to understanding the drug's effects and exploring potential pathways reflects a commitment to advancing cancer care.
Trodelvy's Safety Profile and Current Approvals:
Gilead ( NASDAQ:GILD ) reassures stakeholders by affirming that Trodelvy's safety profile aligns with prior studies, with common adverse events being neutropenia (low white blood cell counts) and diarrhea. It's worth noting that Trodelvy is already approved by U.S. regulators for specific advanced breast cancer and bladder cancer indications. In the first nine months of the previous year, Gilead reported sales of $765 million for Trodelvy, attesting to its commercial success in the approved indications.
Future Prospects and Challenges:
Despite the setback in the second-line lung cancer trial, Gilead remains resilient in its pursuit of innovative solutions for oncology. The ongoing front-line Phase 3 trial combining Trodelvy with Keytruda suggests a strategic focus on exploring novel treatment approaches. However, as emphasized by Parsey, results from this trial are not expected for at least a couple of years, highlighting the prolonged timeline inherent in clinical research.
Conclusion:
Gilead's ( NASDAQ:GILD ) recent trial results for Trodelvy in second-line NSCLC treatment present a nuanced narrative of challenges and opportunities in the evolving landscape of cancer therapeutics. The company's commitment to transparency, ongoing research, and exploration of combination therapies underscores the complexity of addressing lung cancer, one of the most formidable challenges in oncology.
As the full dataset becomes available and discussions with regulators unfold, stakeholders will eagerly anticipate the next chapter in Trodelvy's journey, hoping for breakthroughs that could reshape the future of lung cancer treatment.
GILD 6-Year Resistance IdeaGILD is pushing a 6-year resistance line. It broke through for a few days a year ago before being battered back down. Let's see if it'll make the move stick this time.
GILD: $69 | another Breakthrough for Humanity | Loaded!from Ebola treatment to quick remedy for Corona
truly a mission worth funding and risking on
Stocks pairs trading: AMGN vs GILDIn the biotechnology sector, the differing financial metrics and market positions of Amgen Inc. (AMGN) and Gilead Sciences Inc. (GILD) present an interesting case for investors. It could be strategic to consider buying AMGN while contemplating selling GILD based on their respective financial performances and market dynamics.
Reasons to Prefer AMGN Over GILD:
Earnings Per Share (EPS): AMGN's EPS of $14.06 is significantly higher than GILD's $4.66. This higher EPS indicates better profitability and efficiency in AMGN's operations compared to GILD.
Market Capitalization: AMGN’s market capitalization is $142.36 billion, which is much larger than GILD’s $94.36 billion. A higher market cap often suggests stronger market presence and investor confidence.
Return on Equity (ROE): AMGN shows an exceptional ROE of 133.80%, far outpacing GILD's ROE of 27.08%. This indicates that AMGN is more efficient in converting shareholder investments into profits.
Year-to-Date Performance: AMGN’s year-to-date performance shows a positive change of 1.28%, in contrast to GILD’s -11.79%. This suggests that AMGN has been performing better in the current market environment.
Decision:
Buy 1 AMGN: For its stability, reasonable valuation, and balance between income and growth potential.
Sell 3 GILD: Considering the comparative underperformance and potential challenges in growth and market position.
Long Rubles Big PharmaAs you can see on the presented chart first goes Gilead Sciences, USA Pharmaceutical Giant which we see as the main sorce of income and R&D of USA Pharmaceuticals Industry. Main levels are 82.50, 79.00, 73.50, 69.00. Second is Pfizer, Europe Pharmaceutical giant, main levels are 54.50, 46.50, 28.50. Third is Merck, based, again, in Europe, main levels are 115.00, 80.50. Fourth is Bayer, a multinational Pharmaceutical Giant. Fifth is Life, biopharm company from Russia, main levels are, 9.00, 7.25, 4.70. Sixth is Diod, experimental and natural medicine company, main levels are 24.00, 15.50.
We see a possibility of strong profits in coming quarters, due to the winter season and new R&D activities. Wee see these companies as a good opportunity for a risk oriented investor to hold for about twelve to twenty four months.
GILD - Setting up for multi year run
Monthly chart is setting up nicely.
if it takes out 88, ATH should be quick.
stop loss: 79
GILD Gilead Sciences Options Ahead of EarningsIf you haven`t bought GILD on the Remdesivir approval:
Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week,
I would consider purchasing the 80usd strike price in the money Calls with
an expiration date of 2024-1-19,
for a premium of approximately $4.25.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
